ASCO: Durvalumab plus FLOT beneficial for resectable gastric, GE junction cancer

Published Date: 06 Jun 2025

For patients with resectable gastric or gastroesophageal junction adenocarcinoma, durvalumab plus fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) yields better event-free survival outcomes than FLOT alone, according ...

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Global inequalities found in cancer research funding

2.

Asymptomatic Brain Metastases in EGFR-Mutant NSCLC

3.

Review looks at potential treatment targets in the tumor microenvironment.

4.

Accurately identified high-grade prostate cancer through urine testing.

5.

Pre-operative evaluation of ovarian cancer patients using DWI-MRI is helpful.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot